Minerva Neurosciences, Inc
minervaneurosciences.comWhat Do They Do?
Develops roluperidone, a potential treatment for negative symptoms of schizophrenia, for patients with the disease.
10-K for FY2025, filed Mar 11, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
$17.5MView ↗
- ▲ Now profitable
- vs −$3.3M in Q2 FY2025
Who Do They Compete With?
Competes with GlaxoSmithKline, Sanofi-Aventis, Janssen, Novartis, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Intra-Cellular Therapies, Karuna Therapeutics, Acadia Pharmaceuticals, Lundbeck, Reviva Pharmaceuticals, SyneuRx, Neurocrine, and Denovo Biopharma
10-K for FY2025, filed Mar 11, 2026Current drug therapies for the treatment of schizophrenia mainly target the positive symptoms of the disease. When patients present…View ↗
Loading...
